Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as tilrekimig and rHuPH20
Tilrekimig · 3 trials · 2 indications
Protocol defined asthma exacerbations require treatment with systemic steroids (oral or parenteral) for 3 consecutive days or more; an emergency room or urgent care visit (\<24 hours) that is due to asthma and requires use of systemic corticosteroids as noted above; or an in-patient hospitalization (an admission to an in-patient hospital or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma.
| Arm | Type | Description |
|---|---|---|
| Treatment Arm A Tilrekimig | EXPERIMENTAL | Tilrekimig |
| Treatment Arm B Placebo | PLACEBO_COMPARATOR | Placebo |
| Tilrekimig - Initial treatment period | EXPERIMENTAL | Subcutaneous injections given over 20 Weeks. |
| Dupilumab - Initial treatment period | ACTIVE_COMPARATOR | Subcutaneous injections given over 22 Weeks. |
| Placebo - Initial treatment period | PLACEBO_COMPARATOR | Subcutaneous injections given over 22 Weeks. |
| Tilrekimig - Maintenance Period - Dose A | EXPERIMENTAL | Subcutaneous injections given at Week 24 through Week 48. |
| Tilrekimig - Maintenance Period - Dose B | EXPERIMENTAL | Subcutaneous injections given at Week 24 through Week 48. |
| Placebo - Maintenance Period | PLACEBO_COMPARATOR | Subcutaneous injections given at Week 24 through Week 48. |
| Tilrekimig | EXPERIMENTAL | Subcutaneous injections given over 20 weeks |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous injections given over 20 weeks |
| Name | Type | Description |
|---|---|---|
| tilrekimig | DRUG | subcutaneous injection |
| Placebo | OTHER | subcutaneous injection |
| Dupilumab | DRUG | Subcutaneous Injections at required timepoints based on weight and age. |
| Placebo for Tilrekimig | OTHER | Subcutaneous Injections at required timepoints |
| Placebo for Dupilumab | OTHER | Subcutaneous Injections at required timepoints during initial treatment period. |
Inclusion Criteria Must meet the following asthma criteria: 1. History of persistent, severe asthma for at least 12 months prior to screening as defined by recognized international and / or local guidelines. 2. Must have experienced at least 2 asthma exacerbations requiring treatment with systemic...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
Tilrekimig is an investigational small molecule being studied for the treatment of moderate-to-severe atopic dermatitis (eczema) and severe asthma. It is also being evaluated in healthy adults for pharmacokinetic studies. Tilrekimig is in Phase 3 clinical development and is not yet approved by regulatory authorities.
Tilrekimig is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting multiple clinical trials to evaluate the safety and efficacy of Tilrekimig in patients with atopic dermatitis and asthma.
Tilrekimig is currently in Phase 3 clinical development. Pfizer has initiated several Phase 3 trials for Tilrekimig in atopic dermatitis and asthma, as well as a Phase 1 pharmacokinetic study in healthy volunteers. Tilrekimig is investigational and has not received FDA approval.
Tilrekimig is being studied in several clinical trials. NCT07765888 and NCT07783425 are Phase 3 trials in moderate-to-severe atopic dermatitis. NCT07772921 is a Phase 3 trial in severe asthma. NCT07792941 is a Phase 1 study of single-dose pharmacokinetics in healthy adults when co-mixed with rHuPH20.
Tilrekimig is sometimes studied in combination with rHuPH20, but they are not the same drug. rHuPH20 is a recombinant human hyaluronidase that may be co-mixed with Tilrekimig in clinical trials to evaluate its pharmacokinetic profile. Tilrekimig itself is the investigational small molecule being developed by Pfizer.
The specific molecular target of Tilrekimig has not been disclosed in available clinical trial information. It is described as a small molecule being investigated for its therapeutic effects in atopic dermatitis and asthma. Further details about its mechanism of action are not publicly available at this time.